Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Xencor has appointed Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies has over 25 years of experience in biotechnology and drug development, and recently served as senior vice president of global research at Amgen Inc. He will bring expertise in biologics discovery, multispecific drug candidates, and generative protein design to Xencor.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for the treatment of cancer and autoimmune diseases, has appointed Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies brings over 25 years of experience in biotechnology and drug development, most recently serving as senior vice president of global research at Amgen Inc. [1]

During his tenure at Amgen, Dr. Deshaies oversaw the nomination of over 50 clinical candidates and expanded the company's capabilities for discovering and optimizing multispecific drug candidates. He also applied generative protein design to biologics discovery, contributing significantly to Amgen’s research portfolio. Prior to joining Amgen, Dr. Deshaies was a professor in the Division of Biology and Biological Engineering (BBE) at the California Institute of Technology (Caltech), where he also served as executive officer of the BBE Division. He co-founded Proteolix, which discovered carfilzomib, a selective proteasome inhibitor for the treatment of patients with advanced multiple myeloma, marketed as KYPROLIS®. Dr. Deshaies later founded Cleave Biosciences, focused on modulating protein homeostasis pathways. He has co-authored over 170 scientific papers and is an international leader in the fields of protein homeostasis and targeted protein degradation. [1]

"Ray holds a deep understanding of biological mechanisms and has a long track-record of translating cutting-edge scientific insights into transformative medicines for patients," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We welcome Ray to our Board and look forward to his contributions as we advance our pipeline of novel XmAb® drug candidates through clinical development." [1]

Dr. Deshaies' appointment to Xencor's board highlights the company's commitment to leveraging cutting-edge scientific expertise to drive innovation in its pipeline of engineered antibodies. His extensive background in drug discovery and development positions him to provide valuable strategic guidance as Xencor continues to advance its clinical candidates. [1]

References:
[1] https://www.businesswire.com/news/home/20250731140486/en/Xencor-Appoints-Raymond-Deshaies-Ph.D.-to-Board-of-Directors